MPM Capital
MPM Capital is a biotechnology investment firm that invests in early-stage companies to develop therapeutic technologies in oncology.
Business Model:
Revenue: $4.5M
Employees: 11-50
Rankings
Industries / Tags:
Detailed MPM Capital Information
Geographic Data
Address: 450 Kendall Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Twitter
Linkedin
Crunchbase
Metrics
966,501Website Global Rank
28,580Website Monthly Traffic
Twitter Followers
Description
MPM Capital is a healthcare investment firm that invests in early-stage companies developing therapeutic technologies in oncology. They invest in life sciences companies that seek to cure diseases by translating science into clinical outcomes. They prefer to invest in the biotechnology, healthcare, and life sciences sectors.
Contact Phone:
+16174259200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2019 | TriNetX | Series D | 40M |
| 11/2009 | EndoGastric Solutions | Series E | 0 |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 2/2003 | Synergia Pharma | Series A | 2M |
| 5/2015 | Blade Therapeutics | Seed Round | - |
| 10/2009 | EndoGastric Solutions | Venture Round | 0 |
| 11/2006 | Solasia Pharma | Pre Seed Round | - |
| 3/2004 | Restore Medical | Series C | 26.5M |
| 6/2002 | Cardiac Dimensions | Series B | 12M |
| 6/2013 | Pierian Biosciences | Private Equity Round | 18M |
| 8/2011 | Proteon Therapeutics | Series C | 15.2M |
| 6/2007 | Athersys | Venture Round | 0 |
| 1/2002 | Archus Orthopedics | Series A | - |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 12/2006 | NeoVista | Series C | 41M |
| 3/2003 | Hypnion | Series B | 47.5M |
| 1/2011 | Mitobridge | Seed Round | - |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 1/2012 | CoStim Pharmaceuticals | Seed Round | - |
| 12/2008 | Humanigen | Series D | 12M |
| 10/2004 | PharmAthene | Series B | 50M |
| 6/2014 | True North Therapeutics | Series A | 22M |
| 11/2008 | ARYx Therapeutics | Post-IPO Equity | 21.6M |
| 12/2019 | Triplet Therapeutics | Series A | 49M |
| 7/2007 | Xanodyne | Series A | 25M |
| 1/2008 | Peptimmune | Series D | 8.2M |
| 4/2004 | Affymax | Series C | 20M |
| 10/2015 | 23andMe | Series E | 115M |
| 7/2014 | Cerecor | Series B | 32M |
| 5/2003 | Cellerant Therapeutics | Series A | 10M |
| 5/2001 | SenoRx | Venture Round | 19M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 6/2003 | CryoCor | Series C | 27.5M |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 9/2000 | CryoCor | Series A | 7M |
| 1/2011 | 23andMe | Series C | 9M |
| 10/2005 | Alinea Pharmaceuticals | Series A | 45M |
| 11/2002 | Critical Therapeutics,Inc. | Series A | 10M |
| 9/2008 | Valeritas | Series A | 50M |
| 7/2004 | Arriva Pharmaceuticals | Series D | - |
| 5/2005 | Oxagen | Series B | 0 |
| 10/1999 | Pharmasset | Series B | 3.9M |
| 9/2008 | Innovative Spinal Technologies | Series C | 18M |
| 1/2006 | Xoft | Series C | 0 |
| 3/2017 | Semma Therapeutics | Venture Round | - |
| 3/2016 | Tizona Therapeutics | Series B | 43M |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 11/2004 | Neosil | Series A | 32M |
| 1/2017 | Maverick Therapeutics | Venture Round | 125M |
| 1/2013 | Aratana Therapeutics | Series C | 0 |
| 8/2004 | Ceregene | Series B | 32M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 6/2016 | arGEN-X | Post-IPO Equity | 34.1M |
| 11/2010 | Verastem Oncology | Series A | 16M |
| 7/2005 | Xanodyne | Series A | 170M |
| 2/2006 | ARYx Therapeutics | Series E | 30.4M |
| 7/2012 | Chiasma | Series D | 38.5M |
| 3/2015 | Semma Therapeutics | Series A | 44M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 10/2013 | Mitobridge | Series A | 0 |
| 2/2021 | Orna Therapeutics | Series A | 0 |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 4/2013 | Radius Health | Private Equity Round | 43M |
| 8/2020 | Trishula Therapeutics | Funding Round | - |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 12/2002 | Amphora Discovery | Series B | 12.5M |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 4/2016 | Harpoon Therapeutics | Series A | 15M |
| 11/2011 | Meritage Pharma | Venture Round | 6.5M |
| 5/2008 | SAI Life Sciences | Private Equity Round | 20M |
| 7/2009 | iPierian | Venture Round | 11.5M |
| 4/2016 | Twentyeight-Seven Therapeutics | Series A | - |
| 8/2008 | Peplin | Private Equity Round | 24M |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 12/2018 | Entrada Therapeutics | Series A | 59M |
| 11/2017 | Semma Therapeutics | Series B | 0 |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 1/2020 | BioIntervene | Series A | 30M |
| 10/2003 | Elixir Pharmaceuticals | Series B | 40.5M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 10/2009 | Xanodyne | Venture Round | 0 |
| 2/2008 | Epizyme | Series A | - |
| 11/2020 | Umoja Biopharma | Series A | 53M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 2/2000 | DoubleTwist | Series D | 37M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 3/2020 | ElevateBio | Series B | 170M |
| 7/2008 | Peptimmune | Series D | 8.9M |
| 4/2002 | IntraLuminal Therapeutics | Venture Round | 20M |
| 7/2002 | ARYx Therapeutics | Series C | 25M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 6/2002 | MacroGenics | Venture Round | 12.6M |
| 6/2004 | ARYx Therapeutics | Series D | 55M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 2/2015 | Chiasma | Series E | 70M |
| 7/2005 | Affymax | Series D | 60M |
| 11/2006 | Chiasma | Series C | 44M |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 8/2005 | Innovative Spinal Technologies | Series B | 39M |
| 6/2019 | Frontier Medicines | Series A | 67M |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 5/2005 | Cellerant Therapeutics | Series B | 16M |
| 7/2011 | Verastem Oncology | Series B | 32M |
| 6/2012 | Motus Therapeutics | Series B | 25M |
| 1/2002 | BioXell | Series A | 19.7M |
| 9/2011 | Valeritas | Series C | 150M |
| 12/2016 | TCR2 | Series A | 44.5M |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 3/2020 | ReCode Therapeutics | Series A | 0 |
| 3/2010 | Motus Therapeutics | Series A | 21M |
| 11/2008 | Pacira Pharmaceuticals | Series A | 85M |
| 1/2020 | Orna Therapeutics | Seed Round | 20M |
| 1/2011 | Aratana Therapeutics | Series A | 0 |
| 4/2007 | Radius Health | Series B | 57.5M |
| 9/2007 | JapanBridge | Series A | 6.5M |
| 4/2019 | Dyne Therapeutics | Series A | 50M |
| 3/2015 | Clinical Ink | Venture Round | 20M |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 3/2008 | EKR Therapeutics | Series D | 50M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 12/2002 | Intracel Holdings Corporation | Series B | 16M |
| 4/2011 | Conatus Pharmaceuticals | Series B | 7.5M |
| 4/2015 | True North Therapeutics | Series B | 35M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 3/2006 | Neuromed Pharmaceuticals | Series D | 0 |
| 10/2003 | Cotherix | Series C | 55M |
| 9/2019 | Amphivena Therapeutics | Series C | 0 |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
| 6/2006 | VLST Corporation | Series B | 55M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 9/2011 | Theraclone Sciences | Series B | 10.6M |
| 12/2012 | 23andMe | Series D | 50M |
| 7/2016 | Oncorus | Series A | 57M |
| 1/2008 | PrimeraDx (Primera Biosystems) | Series B | 21M |
| 3/2015 | Vascular Pharmaceuticals | Series A | 9M |
| 3/2009 | Surface Logix | Series E | 15M |
| 11/2012 | Motus Therapeutics | Series B | 8M |
| 3/2008 | TriVascular | Series A | 65M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 11/2019 | Werewolf Therapeutics | Series A | 0 |
| 8/2010 | EndoGastric Solutions | Series F | 0 |
| 6/2009 | EndoGastric Solutions | Venture Round | 3.8M |
| 8/2001 | Eyetech Pharmaceuticals | Series C | 108.5M |
| 6/2020 | Cullinan Oncology | Series B | 98.5M |
| 10/2017 | Cullinan Oncology | Series A | 150M |
| 6/2018 | ITeos Therapeutics | Series B | 0 |
| 8/2003 | Archus Orthopedics | Series B | 18M |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 3/2021 | Aktis Oncology | Series A | 72M |
| 3/2001 | Pharmasset | Series C | 7.4M |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 7/2011 | Nevro | Series B | 58M |
| 12/2011 | Radius Health | Private Equity Round | 21.4M |
| 11/2008 | Radius Health | Series C | 15M |
| 4/2007 | Xoft | Series D | 0 |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 7/2005 | PrimeraDx (Primera Biosystems) | Series A | 11M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 1/2016 | Tizona Therapeutics | Series A | 27M |
| 9/1999 | Pointshare | Series C | 40M |
| 11/2000 | Epigenomics | Venture Round | 24.1M |
| 7/2003 | Tercica | Series B | 44M |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 10/2007 | Allozyne | Series B | 30M |
| 7/2013 | InformedDNA | Seed Round | 3M |
| 12/2005 | Allozyne | Series A | 3.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 5/2009 | Elixir Pharmaceuticals | Series D | 12M |
| 3/2010 | Theraclone Sciences | Venture Round | 1.5M |
| 9/2012 | Selexys Pharmaceuticals Corporation | Series A | 23M |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 3/2016 | Potenza Therapeutics | Venture Round | 30M |
| 9/2008 | ForteBio | Series C | 25M |
| 5/2006 | MacroGenics | Series C | 45M |
| 9/2001 | MacroGenics | Series A | 13.5M |
| 4/2007 | Cellerant Therapeutics | Series B | 0 |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 10/2014 | Atopix Therapeutics | Series A | 0 |
| 11/2011 | Verastem Oncology | Series C | 20M |
| 10/2005 | Cerimon Pharmaceuticals | Series A | 70M |
| 6/2003 | Xoft | Series B | 0 |
| 10/2014 | Raze Therapeutics | Series A | 24M |
| 4/2003 | Epigenomics | Series C | 22.5M |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 3/2005 | Humanigen | Series B | 20M |
| 6/2003 | EndoGastric Solutions | Series A | 5M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 1/2009 | TaiGen Biotechnology | Series C | 0 |
| 3/2004 | TaiGen Biotechnology | Series B | 0 |
| 7/2009 | PharmAthene | Post-IPO Secondary | 19.3M |
| 6/2007 | Ceregene | Series C | 0 |
| 7/2011 | Radius Health | Series C | 66M |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 9/2004 | EndoGastric Solutions | Series B | 12M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 11/2006 | Orexigen Therapeutics, Inc. | Series C | 30M |
| 12/2011 | Aratana Therapeutics | Series B | 15M |
| 3/2007 | Theraclone Sciences | Series B | 29M |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 9/2008 | Humanigen | Series D | 0 |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
| 4/2001 | Genteric | Series B | 22M |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 9/2008 | Nevro | Series A | 21.8M |
| 4/2018 | Tetherex | Series B | 50M |
| 1/2010 | Alnara Pharmaceuticals | Series B | 35M |
| 11/2003 | Neuromed Pharmaceuticals | Series C | 32M |
| 8/2007 | Neuromed Pharmaceuticals | Series E | 0 |
| 10/2009 | PrimeraDx (Primera Biosystems) | Series C | 20M |
| 10/2009 | Epizyme | Series B | 32M |
| 4/2014 | Iconic Therapeutics | Series B | 20M |
| 6/2012 | TriVascular | Series D | 60M |
| 3/2018 | TCR2 | Series B | 0 |
| 3/2010 | Rhythm Pharmaceuticals | Series A | 40M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 3/2021 | ElevateBio | Series C | 525M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 3/2003 | Peptimmune | Series B | 41.2M |
| 5/2023 | ElevateBio | Series D | 0 |
| 9/2010 | Motus Therapeutics | Series A | 19M |
| 7/2003 | Intercell | Series C | 50M |
| 7/2005 | Peptimmune | Series C | 20.4M |
| 10/2013 | Sideris Pharmaceuticals | Series A | 32M |
| 11/2010 | Aires Pharmaceuticals | Series B | 20M |
| 3/2009 | NeoVista | Series D | 18M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2005 | Hypnion | Series B | 0 |
| 7/2014 | Valeritas | Series D | 45M |
| 4/1999 | Omrix Biopharmaceuticals | Venture Round | 20M |
| 11/2019 | SiO2 Materials Science | Venture Round | - |
| 8/2004 | Pharmasset | Series D | 40M |
| 9/2022 | Photys | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 5/2002 | AVEO Oncology | Series A | 15M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 2/2017 | Rhythm Pharmaceuticals | Venture Round | 41M |
| 6/2006 | Peptimmune | Series C | 0 |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 8/2010 | TriVascular | Series C | 60M |
| 11/2009 | TriVascular | Series B | 30M |
| 3/2013 | Nevro | Series C | 0 |
| 11/2009 | Oxagen | Series C | 0 |
| 5/2009 | Proteon Therapeutics | Series B | 50M |
| 10/2007 | Acceleron Pharma | Series C | 31M |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 9/2012 | Vascular Pharmaceuticals | Series A | 16M |
| 4/2004 | Corus Pharma | Series C | 0 |
| 10/2004 | BioXell | Series C | 29M |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 5/2010 | Ntprx | Series B | 43M |
| 11/2010 | iPierian | Series B | 29M |
| 9/2013 | iPierian | Venture Round | 30M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2016 | Blade Therapeutics | Series B | 45M |
| 5/2014 | Proteon Therapeutics | Series D | 0 |
| 11/2013 | TriVascular | Series E | 0 |
| 1/2005 | CHF Solutions | Venture Round | 22.9M |
| 7/2015 | Blade Therapeutics | Series A | 6.5M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 1/2010 | Dragonfly Sciences | Venture Round | - |
| 1/2002 | CryoCor | Series B | 12M |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 9/2022 | Photys Therapeutics | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
